Episode Details
Back to Episodes
NurExone Builds a Commercial Exosome Business Alongside Drug Development | NurExone (TSXV: NRX)
Description
NurExone (TSXV:NRX | OTCQB:NRXBF | FSE: J90) is advancing beyond traditional biotech by building a commercial exosome platform alongside its lead therapeutic program.
In this episode of The Watchlist, listeners will hear CEO Dr. Lior Shaltiel explain how NurExone's U.S. manufacturing strategy, Exo-Top subsidiary, and newly announced Mexico distribution agreement could support both commercial growth and the continued advancement of ExoPTEN for central nervous system injuries.
This discussion covers:
- NurExone's dual-track growth strategy
- Building a U.S.-based exosome manufacturing platform
- The role of Exo-Top in commercial exosome production
- The strategic Mexico distribution agreement
- How commercial revenues could complement therapeutic development
Company Website:
https://www.nurexone.com/
Disclaimer:
This podcast is made in partnership with NurExone. This podcast is for informational purposes only and should not be considered investment advice. Please do your own due diligence before making any investment decisions. For our full disclaimer, visit: https://stockhouse.com/legal/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.